Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT03049540
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose supportive care
- Phase
- Phase 3
- Enrolled
- 100 participants
- Registry
-
NCT03049540
-
- Main results
- Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE
- Other papers using this trial's data
- Prognostic Value and Determinants of High-Sensitivity Cardiac Troponin T in Patients With a Systemic Right Ventricle: Insights From the SERVE Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT03049540. Randomized; quadruple masking; primary purpose supportive care. Start 2017-10-25 (actual); primary completion 2021-10-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function
- Acronym
- SERVE
- Condition
- Heart Defects, Congenital
- Condition
- Transposition of Great Vessels With Ventricular Inversion
- Intervention (Drug)
- Tadalafil 20 MG
- Intervention (Drug)
- Placebo 20 MG
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Collaborator
- Swiss National Science Foundation
Record details
- Record id
cardio:ct-nct03049540- Content hash
db4097888631f939f4a82795af569cf601ebca923643f9146e6a15732ceeea6d